Distributor inventory | Tablet
Voglibose 0.2 mg
Management of type 2 diabetes mellitus; helps control post-meal (postprandial) blood glucose levels, usually as an add-on to diet/exercise and/or other antidiabetic medicines.
Voglibose is an alpha-glucosidase inhibitor that delays the breakdown and absorption of carbohydrates in the small intestine. This reduces the rise in blood sugar after meals and helps improve overall glycaemic control.
Oral tablet. Typically taken just before meals (or with the first bite of food) as prescribed by a doctor. Swallow with water; follow diet and exercise advice and monitor blood glucose regularly.
Common side effects of ZUVOG 0.2 TAB may include:
Use under medical supervision in diabetes. Not recommended in type 1 diabetes or diabetic ketoacidosis. Use with caution in intestinal disorders (inflammatory bowel disease, colonic ulceration), intestinal obstruction/predisposition, or significant digestive disorders. Monitor liver function if advised; stop and seek care if severe abdominal symptoms occur. Hypoglycaemia risk increases when combined with insulin/sulfonylureas—carry glucose and treat lows with glucose (not sucrose).
